Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing calcium blocker, AII receptor blocker and statins

A receptor antagonist, calcium ion antagonist technology, applied in the field of medicine, can solve problems such as unsatisfactory

Inactive Publication Date: 2010-01-06
王丽燕
View PDF4 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the composition has obvious preventive or therapeutic effects, it is still unsatisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing calcium blocker, AII receptor blocker and statins
  • Pharmaceutical composition containing calcium blocker, AII receptor blocker and statins
  • Pharmaceutical composition containing calcium blocker, AII receptor blocker and statins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] Embodiment 1: levamlodipine besylate, telmisartan and atorvastatin calcium tablet

[0093] Name of raw material

Specification 1 Dosage

Specification 2 Dosage

Specification 3 Dosage

levamlodipine besylate

(calculated as levamlodipine)

1.25g

2.5g

5.0g

Telmisartan

20.0g

40.0g

80.0g

Atorvastatin Calcium

(calculated as atorvastatin)

10.0g

20.0g

80.0g

calcium carbonate

155g

140g

75g

pregelatinized starch

18g

18g

18g

Polysorbate 80

5g

5g

5g

Magnesium stearate

0.65g

0.65g

0.65g

Micropowder silica gel

1.25g

1.25g

1.25g

microcrystalline cellulose

37.5g

37.5g

37.5g

sodium starch glycolate

8g

8g

8g

Crospovidone

10g

10g

10g

purified water

Appropriate am...

Embodiment 2

[0096] Embodiment 2: Nitrendipine, candesartan cilexetil and fluvastatin sodium capsules

[0097] Name of raw material

Specification 1 Dosage

Specification 2 Dosage

Specification 3 Dosage

Nitrendipine

5.0g

10.0g

20.0g

candesartan cilexetil

4.0g

8.0g

32.0g

Fluvastatin sodium (calculated as fluvastatin)

20.0g

40.0g

80.0g

calcium carbonate

160g

125g

70g

pregelatinized starch

22g

22g

22g

Polysorbate 80

5.5g

5.5g

5.5g

Magnesium stearate

0.65g

0.65g

0.65g

Micropowder silica gel

1.8g

1.8g

1.8g

Sodium dodecyl sulfate

3.5g

3.5g

3.5g

sodium starch glycolate

8.5g

8.5g

8.5g

Crospovidone

9g

9g

9g

gelatin

9.5g

9.5g

9.5g

purified water

Appropriate amount

Appropr...

Embodiment 3

[0100] Embodiment 3: lacidipine, telmisartan, losartan potassium and rosuvastatin calcium dispersible tablet

[0101] Name of raw material

Specification 1 Dosage

Specification 2 Dosage

Specification 3 Dosage

Lacidipine

4.0g

6.0g

8.0g

Telmisartan

20.0g

40.0g

80.0g

Losartan Potassium

25.0g

50.0g

100.0g

Rosuvastatin Calcium

(Based on rosuvastatin)

5.0g

10.0g

40.0g

calcium carbonate

165g

150g

145g

pregelatinized starch

18.5g

18.5g

18.5g

Polysorbate 80

4.5g

4.5g

4.5g

Magnesium stearate

0.6g

0.6g

0.6g

Micropowder silica gel

1.5g

1.5g

1.5g

microcrystalline cellulose

35g

35g

35g

sodium starch glycolate

8.5g

8.5g

8.5g

Crospovidone

8g

8g

8g

95% ethanol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition containing a calcium channel blocker (CCB) or the mixture thereof, an angiotonin 3II receptor blocker (ARB) or the mixture thereof, statins or the mixture thereof and a pharmaceutically acceptable carrier, wherein the CCB is selected from l-amlodipine, amlodipine, lacidipine, nitrendipine or the mixture thereof; the angiotonin II receptor blocker is selected from telmisartan, losartan, irbesartan, candesartan or the mixture thereof; and the statins are selected from atorvastatin, simvastatin, ruishufatadine, fluvastatin or the mixture thereof. The pharmaceutical composition is used for treating various high blood pressures and preventing or treating cardiovascular and cerebrovascular diseases relevant to the hypertension, reduces the disease rate and / or mortality rate of the cardiovascular and cerebrovascular diseases and also improves the adaptability for a sufferer taking medicine.

Description

technical field [0001] The invention relates to a novel pharmaceutical composition, in particular to a pharmaceutical composition containing a calcium ion antagonist or a mixture thereof, an angiotensin II receptor antagonist or a mixture thereof, and statins or a mixture thereof, belonging to the pharmaceutical field. Background technique [0002] Due to the development of social economy and the change of people's lifestyle, the prevalence rate of hypertension in our country shows a continuous growth trend. According to the results of the national nutrition and health status survey in 2002, the prevalence rate of hypertension among adults in my country reached 18.8%. 160 million hypertensive patients. At present, one person dies of cardiovascular and cerebrovascular diseases every 15 seconds in my country, and the total morbidity and mortality of cardiovascular and cerebrovascular diseases are close to the level of developed countries. Statistics from the Ministry of Healt...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61P3/06A61P3/10A61P9/00A61P9/10A61P9/12A61P13/12A61P27/06
Inventor 王丽燕
Owner 王丽燕
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products